{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:07:34Z","timestamp":1788941254029,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess one-year real-world outcomes of faricimab therapy in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF agents and managed using a treat-and-extend (TAE) regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with treatment-resistant nAMD were switched to faricimab. Functional and structural parameters, including best-corrected visual acuity (BCVA in logMAR), foveal centre point (FCP in \u00b5m), central subfield retinal thickness (CSRT in \u00b5m), and macular volume (MV in mm\u00b3), were recorded over a one-year observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy eyes from 59 patients initiated faricimab therapy between September and December 2022; complete one-year data were available for 60 eyes, with a mean follow-up of 391\u2009\u00b1\u200920 days. Prior to switching, patients had received an average of 42.4\u2009\u00b1\u200925.2 anti-VEGF injections over 70.8\u2009\u00b1\u200945.4 months. Significant structural improvements were observed: FCP decreased from 359\u2009\u00b1\u2009165\u00a0\u03bcm to 283\u2009\u00b1\u2009132\u00a0\u03bcm, CSRT from 414\u2009\u00b1\u2009153\u00a0\u03bcm to 343\u2009\u00b1\u2009116\u00a0\u03bcm, and macular volume from 2.74\u2009\u00b1\u20090.67\u00a0mm\u00b3 to 2.46\u2009\u00b1\u20090.49\u00a0mm\u00b3 (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The mean injection interval increased from 5.8\u2009\u00b1\u20091.8 weeks to 8.2\u2009\u00b1\u20093.3 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), indicating improved disease control. BCVA remained stable (0.45\u2009\u00b1\u20090.37 logMAR vs. 0.44\u2009\u00b1\u20090.39 logMAR;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.35). At the end of follow-up, 37% of eyes achieved a completely dry macula with no residual intra-, subretinal, or sub-RPE fluid. Two eyes developed mild anterior chamber inflammation, which resolved fully under topical corticosteroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching to faricimab in recalcitrant, heavily pretreated nAMD may yield meaningful structural improvements while stabilizing visual acuity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07414-x","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:00:40Z","timestamp":1788940840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration"],"prefix":"10.1007","author":[{"given":"Sebastian","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Liegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Stasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffael","family":"Liegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"7414_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP (2020) Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol 104:1077\u20131084. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314422","journal-title":"Br J Ophthalmol"},{"key":"7414_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"7414_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY (2018) Age-related macular degeneration. Lancet 392:1147\u20131159. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2","journal-title":"Lancet"},{"key":"7414_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, Sivaprasad S, Wykoff CC, Cheung CMG, Sarraf D, Bakri SJ, Chaudhary V (2023) Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond) 37:6\u201316. https:\/\/doi.org\/10.1038\/s41433-022-02020-7","journal-title":"Eye (Lond)"},{"key":"7414_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220\u2013226. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327","journal-title":"Br J Ophthalmol"},{"key":"7414_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D, Agostini HT, Stahl A (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611","journal-title":"Clin Ophthalmol"},{"key":"7414_CR7","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","volume":"17","author":"GD Panos","year":"2023","unstructured":"Panos GD, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku WM (2023) Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies. Drug Des Devel Ther 17:2861\u20132873. https:\/\/doi.org\/10.2147\/DDDT.S427416","journal-title":"Drug Des Devel Ther"},{"key":"7414_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"7414_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S-J, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R (2024) TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 131:914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"7414_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S (2020) Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 138:955\u2013963. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2685","journal-title":"JAMA Ophthalmol"},{"key":"7414_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"29","author":"F Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723\u2013731. https:\/\/doi.org\/10.1097\/IAE.0b013e3181a2c1c3","journal-title":"Retina"},{"key":"7414_CR12","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199\u20132205. https:\/\/doi.org\/10.1016\/j.ophtha.2008.07.007","journal-title":"Ophthalmology"},{"key":"7414_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/bjo.2011.204685","volume":"96","author":"JL Gasperini","year":"2012","unstructured":"Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, Walsh AC, Hwang J, Sadda SR (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14\u201320. https:\/\/doi.org\/10.1136\/bjo.2011.204685","journal-title":"Br J Ophthalmol"},{"key":"7414_CR14","doi-asserted-by":"publisher","first-page":"e40100","DOI":"10.7759\/cureus.40100","volume":"15","author":"AM Cheng","year":"2023","unstructured":"Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV (2023) Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration. Cureus 15:e40100. https:\/\/doi.org\/10.7759\/cureus.40100","journal-title":"Cureus"},{"key":"7414_CR15","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","volume":"12","author":"S Inoda","year":"2023","unstructured":"Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, Takahashi H, Takayama T, Kawashima H, Yanagi Y (2023) Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History. Ophthalmol Ther 12:2703\u20132712. https:\/\/doi.org\/10.1007\/s40123-023-00779-w","journal-title":"Ophthalmol Ther"},{"key":"7414_CR16","doi-asserted-by":"publisher","unstructured":"Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, Kusuhara S, Nakamura M (2023) Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration. J Clin Med 12. https:\/\/doi.org\/10.3390\/jcm12155145","DOI":"10.3390\/jcm12155145"},{"key":"7414_CR17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J (2024) Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 262:2153\u20132162. https:\/\/doi.org\/10.1007\/s00417-024-06421-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7414_CR18","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, Miyata M, Takahashi A, Kido A, Muraoka Y, Miyake M, Ooto S, Tsujikawa A (2023) Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep 13:21128. https:\/\/doi.org\/10.1038\/s41598-023-48190-6","journal-title":"Sci Rep"},{"key":"7414_CR19","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.ajoint.2024.100074","volume":"1","author":"C Weber","year":"2024","unstructured":"Weber C, Schipper P, Stasik I, Weinhold L, Bulirsch L, Thiele S, Holz F, Liegl R (2024) Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study. AJO Int 1:100074. https:\/\/doi.org\/10.1016\/j.ajoint.2024.100074","journal-title":"AJO Int"},{"key":"7414_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10792-025-03525-2","volume":"45","author":"N Bleidi\u00dfel","year":"2025","unstructured":"Bleidi\u00dfel N, Weichenberger M, Maier M, Spielberg N, Feucht N (2025) Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy. Int Ophthalmol 45:177. https:\/\/doi.org\/10.1007\/s10792-025-03525-2","journal-title":"Int Ophthalmol"},{"key":"7414_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, Bottini A, Chin Yee D, Mukkamala K (2023) Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol 17:1287\u20131293. https:\/\/doi.org\/10.2147\/OPTH.S409822","journal-title":"Clin Ophthalmol"},{"key":"7414_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA (2024) Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 262:43\u201351. https:\/\/doi.org\/10.1007\/s00417-023-06222-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7414_CR23","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Mein L, Sheth VS, Wolfe JD, Singer MA, Danzig CJ (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u2009\u2013\u20096 month results. Eye (Lond) 37:3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye (Lond)"},{"key":"7414_CR24","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G (2024) One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration. Ophthalmol Ther 13:2985\u20132997. https:\/\/doi.org\/10.1007\/s40123-024-01036-4","journal-title":"Ophthalmol Ther"},{"key":"7414_CR25","doi-asserted-by":"publisher","unstructured":"Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, Stillenmunkes R, Munk MR, Paris A, Menghini M, Artemiev D, Ebneter A, Cattaneo J, de Oliveira Figueiredo EC, Eandi CM, Fr\u00f6hlich J, Feltgen N, Spitznagel T, Somfai GM, Cozzi M, Zweifel S, Weinberger A, Garweg JG (2025) One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. https:\/\/doi.org\/10.1016\/j.oret.2025.03.015. Ophthalmol Retina","DOI":"10.1016\/j.oret.2025.03.015"},{"key":"7414_CR26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB (2023) One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol 17:2201\u20132208. https:\/\/doi.org\/10.2147\/OPTH.S424315","journal-title":"Clin Ophthalmol"},{"key":"7414_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H (2024) One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol 68:83\u201390. https:\/\/doi.org\/10.1007\/s10384-023-01040-4","journal-title":"Jpn J Ophthalmol"},{"key":"7414_CR28","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T (2024) One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep 14:11681. https:\/\/doi.org\/10.1038\/s41598-024-62559-1","journal-title":"Sci Rep"},{"key":"7414_CR29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesb\u00f8ll C (2023) Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway. Clin Ophthalmol 17:1465\u20131474. https:\/\/doi.org\/10.2147\/OPTH.S409103","journal-title":"Clin Ophthalmol"},{"key":"7414_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajo.2012.07.009","volume":"155","author":"HJ Cho","year":"2013","unstructured":"Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, Lee JH (2013) Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol 155:118\u2013126e1. https:\/\/doi.org\/10.1016\/j.ajo.2012.07.009","journal-title":"Am J Ophthalmol"},{"key":"7414_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000517187","volume":"244","author":"T Nizawa","year":"2021","unstructured":"Nizawa T, Kitahashi M, Baba T, Iwase T, Kubota-Taniai M, Hattori Y, Shiko Y, Kawasaki Y, Iwase T, Sato T, Ogawa S, Sugawara T, Yamamoto S (2021) Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy. Ophthalmologica 244:347\u2013360. https:\/\/doi.org\/10.1159\/000517187","journal-title":"Ophthalmologica"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07414-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07414-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07414-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:00:41Z","timestamp":1788940841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07414-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":31,"alternative-id":["7414"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07414-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol was reviewed and approved by the ethics review board at the University of Bonn, \u201cEthikkommission der Universit\u00e4t Bonn\u201d, reference number 258\/21.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH, CL, IS and RL certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent- licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No written informed consent was obtained from participants due to the retrospective nature of this study and because the data used did not allow for the identification of patients. A waiver of informed consent was granted by the local ethics committee. The research was conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH, CL, IS and RL certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent- licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.FGH has received honoraria or research grants from the following: Acucela (C, F), Allergan (F), Apellis (C, F), Bayer (C, F), Boehringer-Ingelheim (C), Bioeq\/Formycon (F, C), CenterVue (F), Ellex (F), Roche\/Genentech (C, F), Geuder (C, F), Graybug (C), Gyroscope (C), Heidelberg Engineering (C, F), IvericBio (C, F), Kanghong (C, F), LinBioscience (C), NightStarX (F), Novartis (C, F), Optos (F), Oxurion (C), Pixium Vision (C, F), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (F, C), but none of this is related to the current study.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}